Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1559-0100
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study ; day:28 ; month:9 ; year:2020 ; pages:1-10
Endocrine ; (28.9.2020), 1-10
- Urheber
-
Kuhn, Emmanuelle
Caron, Philippe
Delemer, Brigitte
Raingeard, Isabelle
Lefebvre, Hervé
Raverot, Gérald
Cortet-Rudelli, Christine
Desailloud, Rachel
Geffroy, Clementine
Henocque, Robin
Brault, Yves
Brue, Thierry
Chanson, Philippe
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12020-020-02501-3
- URN
-
urn:nbn:de:101:1-2020121908570300099543
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kuhn, Emmanuelle
- Caron, Philippe
- Delemer, Brigitte
- Raingeard, Isabelle
- Lefebvre, Hervé
- Raverot, Gérald
- Cortet-Rudelli, Christine
- Desailloud, Rachel
- Geffroy, Clementine
- Henocque, Robin
- Brault, Yves
- Brue, Thierry
- Chanson, Philippe
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Acromegaly
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
Acromegaly
Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Safety review: Dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
Somatostatin analogs in cancer management : 16 tables
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review
The Coordination Abilities of New Cyclic Analogs of Somatostatin
A case of malignant insulinoma responsive to somatostatin analogs treatment
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience